Key result
Grade 2-4 hand-foot syndrome and oral mucositis during pegylated liposomal doxorubicin therapy was associated with a higher clinical benefit rate (77.7% vs 11.1%; P<0.001) than grade 0/1 toxicity.
Why the study?
Does the severity of hand-foot syndrome and mucositis predict the efficacy of pegylated liposomal doxorubicin in patients with recurrent ovarian cancer?
Cohort (n=27)
Does the severity of hand-foot syndrome and mucositis predict the efficacy of pegylated liposomal doxorubicin in patients with recurrent ovarian cancer?
Severity of hand-foot syndrome and mucositis may predict pegylated liposomal doxorubicin response; hypothesis-generating and should not yet change practice in recurrent ovarian cancer.
AIM: Hand-foot syndrome (HFS) induced by chemotherapy and molecule-targeting drugs is correlated with treatment efficacy. We conducted a retrospective analysis to evaluate the relationship between HFS and efficacy of pegylated liposomal doxorubicin (PLD) for recurrent ovarian cancer. METHODS: Patients were treated with PLD between July 2009 and May 2014. We evaluated patient characteristics, incidence of adverse events, clinical benefit (rate of complete response, partial response, and stable disease), progression-free survival, and overall survival. RESULTS: Twenty-seven patients were included in the study. Median age was 63 years (range, 41-77 years). The median number of cycles of PLD was 3 (range, 1-6). The clinical benefit rate was 33.3%, and progressive disease was noted in 18 patients (66.7%). Median overall survival was 6.7 months (range, 1.1-41 months). Compared with patients with grade 0/1 HFS and oral mucositis, patients with grade 2-4 toxicity (n = 9, 33.3%) had a significantly higher rate of clinical benefit (11.1% vs 77.7%; P < 0.001) and a longer median overall survival (3.7 months vs 20.8 months; P < 0.001). CONCLUSIONS: Severity of HFS and mucositis may be a predictive marker of PLD efficacy. The prevention and management of HFS and mucositis are important for continued treatment.
No takes yet. Share an insight, caveat, or question.
Yamada et al. (2017) conducted a cohort in recurrent ovarian cancer (n=27). Grade 2-4 hand-foot syndrome and oral mucositis vs. Grade 0/1 hand-foot syndrome and oral mucositis was evaluated on clinical benefit rate (p=<0.001). Grade 2-4 hand-foot syndrome and oral mucositis during pegylated liposomal doxorubicin therapy was associated with a higher clinical benefit rate (77.7% vs 11.1%; P<0.001) than grade 0/1 toxicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: